Linker ID	LIN0KRUKR
Linker Name	Mal-amido-PEG8-acid
Linker Type	Unclear
Antibody-Linker Relation	Unclear
Structure
	3D MOL			2D MOL
Formula	C26H44N2O13
Isosmiles	O=C(O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(CCN1C(C=CC1=O)=O)=O
PubChem CID	51340955
InChI	InChI=1S/C26H44N2O13/c29-23(3-6-28-24(30)1-2-25(28)31)27-5-8-35-10-12-37-14-16-39-18-20-41-22-21-40-19-17-38-15-13-36-11-9-34-7-4-26(32)33/h1-2H,3-22H2,(H,27,29)(H,32,33)
InChIKey	ARKUDJPBDMAVBL-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight		592.639	Polar area		177.62
	Complexity		685.5499552	xlogp Value		-0.9748
	Heavy Count		41	Rot Bonds		30
	Hbond acc		12	Hbond Donor		2

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 20%
Method Description	ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 10 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 6 mg/kg on day 1, dayv8 and day 15. time lasted 57 days.
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 80%
Method Description	ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 10 mg/kg on day 1, dayv8 and day 15. time lasted 57 days.
In Vivo Model	MDA-MB-231 Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 30%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 6 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 60%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 10 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 60%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 10 mg/kg was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 80%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 6 mg/kg was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 90%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 3 mg/kg was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.07 nM	Positive HER2 expression (HER2+++/++)
Method Description	NCI-N87 (HER2+++)
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Ref 1	Antibody-drug conjugates